tenofovir has been researched along with Osteoporosis in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.03) | 29.6817 |
| 2010's | 19 (57.58) | 24.3611 |
| 2020's | 13 (39.39) | 2.80 |
| Authors | Studies |
|---|---|
| Dokmetas, I; Gunduz, A; Kuran, B; Oncul, A; Ozcan, SN; Pehlivan, O; Sevgi, DY; Terlemez, R | 1 |
| Chen, M; Meng, W; Song, Y; Xie, R; Zhang, F; Zhang, H | 1 |
| Guo, P; Qin, X; Yan, H; Yang, X; Zhang, X | 1 |
| Chang, J; Delgado, H; Do, D; Huynh, A; Kanimian, N | 1 |
| Li, L; Ma, W; Wei, D; Ye, P; Zeng, J | 1 |
| Boileau, M; Lambotte, O; Pouvelle, A; Robert, C; Routier, E | 1 |
| Guan, W; Li, T; Li, Y; Lin, Q; Song, X; Xu, Y; Yu, W; Zhang, Y; Zhang, Z | 1 |
| Bernasconi, E; Burkhalter, F; Calmy, A; Fellay, J; Günthard, HF; Hasse, B; Kahlert, CR; Kouyos, RD; Lamy, O; Ledergerber, B; Marzolini, C; Ryom, L; Schoepf, IC; Schwenke, JM; Tarr, PE; Thorball, CW; Wandeler, G | 1 |
| Arpadi, SM; Shiau, S; Yin, MT | 1 |
| Baranek, B; Cheung, AM; Mishra, S; Tan, DH; Wang, S | 1 |
| Apornpong, T; Avihingsanon, A; Buranasupkajorn, P; Chaiwatanarat, T; Han, WM; Jadwattanakul, T; Jantrapakde, J; Kerr, SJ; Phanuphak, N; Phanuphak, P; Ramautarsing, R; Ruxrungtham, K; Sunthornyothin, S; Teeratakulpisarn, N; Wattanachanya, L | 1 |
| Gan, C; Han, Z; He, P; Huang, M; Ke, R; Lu, W; Luo, W; Shu, J; Xia, J; Xian, J; Xu, Z | 1 |
| Duan, L; Li, XF; Lin, W; Liu, JZ; Ren, DC; Song, M; Zhan, ZR | 1 |
| Hsu, YC; Nguyen, MH; Wei, MT | 1 |
| Badiou, S; Bado, G; Ciaffi, L; Cournil, A; Delaporte, E; Diouf, A; Eymard-Duvernay, S; Héma, A; Kabore, FN; Koulla-Shiro, S; Zoungrana, J | 1 |
| Adams-Huet, B; Bedimo, RJ; Brown, G; Castanon, R; Farukhi, I; Maalouf, NM; Moore, T; Poindexter, J; Tebas, P; Turner, D | 1 |
| Chan, PA; Harrison, LC; Patel, RR; Powderly, WG; Presti, R | 1 |
| Aboud, M; Angelis, K; Cupo, M; De Wet, J; Gartland, M; Kahl, LP; Lupo, S; McComsey, GA; Parks, D; Poggio, MC; Vandermeulen, K; Wynne, B | 1 |
| Angeli, P; Fasolato, S; Gambino, C; Mareso, S; Piano, S; Pilutti, C; Pontisso, P; Romano, A; Sartori, L; Stanco, M; Tonon, M | 1 |
| Ikeda, A; Kikuchi, A; Komatsu, A; Matsushita, S; Minami, C; Tan, M | 1 |
| Ahn, SH; Cho, YK; Choi, W; Han, KH; Hong, GY; Jang, JY; Jin, SY; Jung, YK; Kim, DJ; Kim, HS; Kim, JH; Kim, KH; Kim, MY; Kim, W; Kim, YJ; Kweon, YO; Lee, BS; Lee, JW; Lee, KS; Lee, WS; Lim, YS; Park, NH; Park, SJ; Sohn, JH; Um, SH; Yang, JM; Yim, HJ; Yoon, SK | 1 |
| Chang, MS; Cheung, R; Hsu, H; Le, AK; Nguyen, MH; Nguyen, P; Wei, MT; Wong, C; Zhang, JQ | 1 |
| Holmes, DT; Jiang, SY; Kendler, DL; Saeedi, R | 1 |
| Bonjoch, A; Clotet, B; Domingo, P; Echeverría, P; Escrig, R; Gutiérrez, M; Mateo, G; Negredo, E; Pérez-Álvarez, N; Puig, J | 1 |
| Bae, HS; Chan, LS; Chang, M; Fong, TL; Huh, B; Lee, S; Lim, C; Shinada, S; Tien, C; Xu, JJ | 1 |
| Brooks, JT; Bush, T; Conley, L; Escota, GV; Hammer, J; Henry, K; Kojic, EM; Lichtenstein, KA; Mondy, K; Önen, N; Overton, ET; Patel, P; Wood, KC | 1 |
| Anderson, PH; Ebeling, PR; Emery, S; Fairley, CK; Kimlin, MG; Klassen, KM | 1 |
| Lavae-Mokhtari, M; Mohammad-Khani, S; Schmidt, RE; Stoll, M | 1 |
| Gopalakrishnan, R; Grigsby, IF; Mansky, KC; Mansky, LM; Pham, L | 1 |
| Bonjoch, A; Clotet, B; del Rio, L; di Gregorio, S; Estany, C; Figueras, M; Gómez, G; Negredo, E; Perez-Alvarez, N; Puig, J; Rosales, J | 1 |
| Daar, ES; Ha, B; Jahed, NC; Kitch, D; McComsey, GA; Melbourne, K; Myers, L; Sax, PE; Tebas, P; Tierney, C | 1 |
| Chau, Q; Fessel, WJ; Leong, D | 1 |
| Powderly, WG | 1 |
7 review(s) available for tenofovir and Osteoporosis
| Article | Year |
|---|---|
Comparison of renal safety and bone mineral density of tenofovir and entecavir in patients with chronic hepatitis B: a systematic review and meta-analysis.
Topics: Antiviral Agents; Bone Density; Bone Diseases, Metabolic; Hepatitis B, Chronic; Humans; Kidney; Osteoporosis; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Tenofovir-induced osteopenia and hyperparathyroidism: A case report and literature review.
Topics: Adenine; Bone Diseases, Metabolic; Calcium; Humans; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Osteoporosis; Tenofovir | 2022 |
Bone Update: Is It Still an Issue Without Tenofovir Disoproxil Fumarate?
Topics: Adolescent; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone and Bones; Bone Density; Child; Female; Fractures, Bone; HIV Infections; Humans; Osteoporosis; Risk Factors; Tenofovir | 2020 |
The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis.
Topics: Anti-HIV Agents; Bone Density; Humans; Osteoporosis; Tenofovir | 2020 |
Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.
Topics: Adenine; Age Factors; Alanine; Antiviral Agents; Bone Density; Clinical Decision-Making; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney; Male; Osteoporosis; Patient Safety; Pregnancy; Renal Insufficiency; Risk Factors; Tenofovir; Treatment Outcome | 2017 |
Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: a case report and review of the literature.
Topics: Anti-HIV Agents; Biomarkers; Female; Follow-Up Studies; HIV Infections; Humans; Medication Adherence; Middle Aged; Osteoporosis; Patient Outcome Assessment; Pre-Exposure Prophylaxis; Tenofovir | 2018 |
Osteoporosis and bone health in HIV.
Topics: Absorptiometry, Photon; Acquired Immunodeficiency Syndrome; Adenine; Alcohol Drinking; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Bone Density Conservation Agents; Female; Humans; Inflammation; Male; Organophosphonates; Osteomalacia; Osteoporosis; Osteoporotic Fractures; Smoking; Tenofovir; Weight Loss | 2012 |
7 trial(s) available for tenofovir and Osteoporosis
| Article | Year |
|---|---|
Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression.
Topics: Adult; Anti-Retroviral Agents; Bone Density; Bone Density Conservation Agents; Cell Proliferation; Cells, Cultured; Cyclic AMP-Dependent Protein Kinase Catalytic Subunits; Female; HIV Infections; Humans; Male; MAP Kinase Signaling System; MicroRNAs; Middle Aged; Osteoclasts; Osteogenesis; Osteoporosis; RANK Ligand; Smad3 Protein; Tenofovir; Zoledronic Acid | 2021 |
TDF and quantitative ultrasound bone quality in African patients on second line ART, ANRS 12169 2LADY sub-study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Bone and Bones; Bone Demineralization, Pathologic; Bone Density; Burkina Faso; Cameroon; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Osteoporosis; Senegal; Tenofovir | 2017 |
Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Drug Substitution; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Osteoporosis; Oxazines; Pelvic Bones; Piperazines; Pyridones; Rilpivirine; Spine; Tenofovir; Treatment Outcome | 2018 |
Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection.
Topics: Absorptiometry, Photon; Adult; Alanine Transaminase; Antiviral Agents; Bone Density; Bone Diseases, Metabolic; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Female; Glomerular Filtration Rate; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Hip; Humans; Lumbar Vertebrae; Male; Maleates; Middle Aged; Organophosphonates; Osteoporosis; Renal Insufficiency; Sustained Virologic Response; Tenofovir; Treatment Outcome | 2019 |
Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study).
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Osteoporosis; Pilot Projects; Tenofovir; Treatment Outcome | 2014 |
Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV.
Topics: Adult; Anti-HIV Agents; Body Mass Index; Bone Density; Calcitriol; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Hip Joint; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Osteoporosis; Prospective Studies; Tenofovir; Vitamin D | 2016 |
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG
Topics: Absorptiometry, Photon; Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Bone Density; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Fractures, Bone; HIV Infections; Humans; Intention to Treat Analysis; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Osteoporosis; Pyridines; Risk Factors; Ritonavir; Tenofovir; Viral Load | 2011 |
19 other study(ies) available for tenofovir and Osteoporosis
| Article | Year |
|---|---|
The Prevalence and Associated Factors of Reduced Bone Mineral Density (BMD) Among Men with Suppressed Viral Load Taking Antiretroviral Therapy.
Topics: Absorptiometry, Photon; Aged; Anti-HIV Agents; Bone Density; Cross-Sectional Studies; Female; HIV Infections; Humans; Male; Osteoporosis; Prevalence; Tenofovir; Viral Load | 2022 |
Prevalence and Risk Factors of Low Bone Mineral Density in HIV/AIDS Patients: A Chinese Cross-Sectional Study.
Topics: Absorptiometry, Photon; Acquired Immunodeficiency Syndrome; Bone Density; Bone Diseases, Metabolic; Cholesterol; Cross-Sectional Studies; HIV Infections; Humans; Lipoproteins, HDL; Middle Aged; Osteoporosis; Prevalence; Risk Factors; Tenofovir | 2022 |
A retrospective analysis of bone loss in tenofovir-emtricitabine therapy for HIV PrEP.
Topics: Anti-HIV Agents; Bone Diseases, Metabolic; Emtricitabine; HIV Infections; Humans; Osteoporosis; Retrospective Studies; Tenofovir | 2022 |
Tenofovir-induced osteoporosis fracture in a patient using PrEP: A pitfall for the oncologist.
Topics: Anti-HIV Agents; HIV Infections; Humans; Oncologists; Osteoporosis; Tenofovir | 2023 |
Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males.
Topics: Adult; Anti-HIV Agents; Bone Density; Cancellous Bone; East Asian People; HIV Infections; Humans; Lamivudine; Male; Muscles; Osteoporosis; Retrospective Studies; Sarcopenia; Stavudine; Tenofovir; Young Adult | 2023 |
Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV: The Swiss HIV Cohort Study.
Topics: Bone Density; Bone Diseases, Metabolic; Cohort Studies; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Osteoporosis; Risk Factors; Switzerland; Tenofovir | 2023 |
Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Bone Density; Female; Femur Neck; HIV Infections; Humans; Male; Middle Aged; Osteoporosis; Prevalence; Prospective Studies; Tenofovir; Thailand | 2020 |
Association between Nonalcoholic Fatty Liver Disease and Bone Mineral Density in HIV-Infected Patients Receiving Long-term TDF-Based Antiretroviral Therapy.
Topics: Adult; Anti-HIV Agents; Bone Density; China; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Osteoporosis; Tenofovir | 2021 |
The Differential Effects of Human Immunodeficiency Virus and Hepatitis C Virus on Bone Microarchitecture and Fracture Risk.
Topics: Bone Density; Cancellous Bone; Coinfection; Cross-Sectional Studies; Fractures, Bone; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Male; Middle Aged; Osteoporosis; Prospective Studies; Risk Factors; Tenofovir | 2018 |
Assessment of bone mineral density in patients with cirrhosis treated with third-generation nucleos(t)ide analogues: comparison between tenofovir and entecavir.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Antiviral Agents; Bone Density; Female; Guanine; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Parathyroid Hormone; Prospective Studies; Risk Assessment; Tenofovir; Vitamin D Deficiency; Young Adult | 2018 |
Osteoporosis-Related Fractures in HIV-Infected Patients Receiving Long-Term Tenofovir Disoproxil Fumarate: An Observational Cohort Study.
Topics: Adult; Aged; Anti-HIV Agents; Cohort Studies; Drug Administration Schedule; Female; Fractures, Bone; HIV Infections; Humans; Japan; Longitudinal Studies; Male; Middle Aged; Osteoporosis; Tenofovir | 2018 |
Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Asian People; Bone Diseases, Metabolic; Female; Follow-Up Studies; Guanine; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Osteoporosis; Proportional Hazards Models; Retrospective Studies; Tenofovir; Treatment Outcome; United States | 2019 |
Fibroblast growth factor 23 is elevated in tenofovir-related hypophosphatemia.
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Fanconi Syndrome; Fibroblast Growth Factor-23; Fibroblast Growth Factors; HIV Infections; Humans; Hypophosphatemia; Male; Organophosphonates; Osteomalacia; Osteoporosis; Tenofovir | 2014 |
Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling.
Topics: Absorptiometry, Photon; Adenine; Adult; Aged; Antiviral Agents; Asian People; Bone Density; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Kidney Tubules, Proximal; Male; Middle Aged; Organophosphonates; Osteoporosis; Phosphates; Prospective Studies; Renal Reabsorption; Risk Factors; Tenofovir; Time Factors; Treatment Outcome; Young Adult | 2015 |
High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years Among HIV-Infected Persons in the Era of Modern Antiretroviral Therapy.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Apolipoproteins E; Bone Density; Bone Diseases, Metabolic; Case-Control Studies; CD4 Lymphocyte Count; Female; HIV; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Nutrition Surveys; Osteoporosis; Risk Factors; RNA, Viral; Tenofovir; United States | 2016 |
[Acute renal failure and hypercalcemia in an AIDS patient on tenofovir and low-dose vitamin D therapy with immune reconstitution inflammatory syndrome].
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adenine; Adrenal Cortex Hormones; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Calcium; Cholecalciferol; Cyclopropanes; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; Humans; Hypercalcemia; Immune Reconstitution Inflammatory Syndrome; Kidney Function Tests; Mycobacterium avium-intracellulare Infection; Organophosphonates; Osteoporosis; Tenofovir | 2009 |
Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts.
Topics: Adenine; Animals; Anti-HIV Agents; Aspartate Aminotransferase, Mitochondrial; Bone Density; Cell Survival; Cells, Cultured; Chromogranins; Down-Regulation; Gene Expression; GTP-Binding Protein alpha Subunits, Gs; Mice; Oligonucleotide Array Sequence Analysis; Organophosphonates; Osteoclasts; Osteoporosis; RNA, Small Nucleolar; Tenofovir | 2010 |
High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study.
Topics: Absorptiometry, Photon; Adenine; Aged; Antiretroviral Therapy, Highly Active; Bone Density; Cohort Studies; Cross-Sectional Studies; Disease Progression; Female; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Osteoporosis; Prevalence; Radionuclide Imaging; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2010 |
Association of osteonecrosis and osteoporosis in HIV-1-infected patients.
Topics: Absorptiometry, Photon; Adenine; Alcohol Drinking; Anti-HIV Agents; California; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Osteonecrosis; Osteoporosis; Prednisolone; Tenofovir | 2011 |